The company will conduct a trial aimed at transplanting OPCs to the site of a spinal cord injury and examining whether it could help restore some function to the patient.
Asterias Biotherapeutics is a biotechnology company focused on the emerging field of regenerative medicine.
More Articles on Spine:
Hospital for Special Surgery Names Dr. Todd Albert Surgeon-in-Chief
Costs for SI Joint Disruption, Sacroiliitis About $270M Over 5 Years
The Robotic Difference: How New Technology Could Impact Spine
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.